Evidence map›Paper›PMID 37896812›Full record

Trial reportViruses2023

Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm.

Lesley E Jackson, Nitasha Khullar, Timothy Beukelman, Chris Chapleau, Abhishek Kamath, Randy Q Cron, Walter Winn Chatham

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04362111 (Early Treatment of Cytokine Storm Syndrome in Covid-19), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04362111 phase3completednot on this map

Early Treatment of Cytokine Storm Syndrome in Covid-19

TypeinterventionalSponsorUniversity of Alabama at BirminghamRan2020 to 2023Enrolled32ConditionsCytokine Storm, COVID-19ArmsAnakinra, Normal saline
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Observational
  2. Cytokine storm.Nature reviews. Disease primers · 2026
    Review
  3. Article
  4. Article
  5. Role of DOCK8 in cytokine storm syndromes.The Journal of allergy and clinical immunology · 2025
    Article
  6. Immunity and Coagulation in COVID-19.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lesley E JacksonDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0002-9373-7620
Nitasha KhullarDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Timothy BeukelmanDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Chris ChapleauUAB Hospital Pharmacy, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Abhishek KamathHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0001-6408-3253
Randy Q CronDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0003-2661-3086
Walter Winn ChathamDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
University of Alabama at Birmingham · USChildren's of Alabama · USUniversity of Alabama at Birmingham Hospital · US

Funding

Training Program in Rheumatic and Musculoskeletal Diseases ResearchT32AR069516 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI John D Mountz · 2016 to 2026
$2.6M
NIAMS NIH HHS T32 AR069516
6 · The paper itself

Abstract

(1) Background: Some severe COVID-19 patients develop hyperinflammatory cytokine storm syndrome (CSS). We assessed the efficacy of anakinra added to standard of care (SoC) in hospitalized COVID-19 CSS patients. (2) Methods: In this single-center, randomized, double-blind, placebo-controlled trial (NCT04362111), we recruited adult hospitalized patients with SARS-CoV-2 infection, evidence of pneumonia, new/increasing oxygen requirement, ferritin ≥ 700 ng/mL, and at least three of the following indicators: D-dimer ≥ 500 ng/mL, platelet count < 130,000/mm

Indexed as

COVID-19AdultCytokine Release SyndromeDexamethasoneFemaleHumansInterleukin 1 Receptor Antagonist ProteinInterleukin-6MaleMiddle AgedSARS-CoV-2Treatment OutcomeDexamethasoneInterleukin 1 Receptor Antagonist ProteinInterleukin-6anakinraantiviral treatmentSARS-CoV-2

Identifiers

PMID37896812
PMCPMC10612044
OpenAlexW4387234996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.